Emactuzumab
- Generic Name
- Emactuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1448221-67-7
- Unique Ingredient Identifier
- 6FY6EI1X8R
- Background
Emactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors).
- Associated Conditions
- -
- Associated Therapies
- -
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- SynOx Therapeutics Limited
- Target Recruit Count
- 128
- Registration Number
- NCT05417789
- Locations
- πΊπΈ
Sarcoma Oncology Research Center, LLC, Los Angeles, California, United States
πΊπΈUniversity of Minnesota, Minneapolis, Minnesota, United States
π§πͺCliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Brussels, Belgium
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
- Conditions
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT03768063
- Locations
- πΊπΈ
Univ of Alabama at Birmingham; UAB Comprehensive Cancer Ctr, Birmingham, Alabama, United States
πΊπΈHonorHealth Research Institute - Pima - Virginia G. Piper Cancer Care Network, Scottsdale, Arizona, United States
πΊπΈUniversity of Arkansas for Medical Sciences; Winthrop Rockefeller Cancer Institute, Little Rock, Arkansas, United States
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT03369964
- Locations
- πΊπΈ
City of Hope Comprehensive Cancer Center, Duarte, California, United States
πΊπΈTennessee Oncology, Nashville, Tennessee, United States
A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT02760797
- Locations
- πΊπΈ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
πΊπΈUniversity Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
π«π·Institut Gustave Roussy; Sitep, VILLEJUIF Cedex, France
A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 221
- Registration Number
- NCT02323191
- Locations
- πΊπΈ
Dana Farber - Harvard, Boston, Massachusetts, United States
πΊπΈMemorial Sloan-Kettering Cancer Center Breast & Imaging Center, New York, New York, United States
πͺπΈClinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.